[go: up one dir, main page]

DE60312684D1 - Plazenta-wachstumsfaktor als target für die behandlung von osteoporose - Google Patents

Plazenta-wachstumsfaktor als target für die behandlung von osteoporose

Info

Publication number
DE60312684D1
DE60312684D1 DE60312684T DE60312684T DE60312684D1 DE 60312684 D1 DE60312684 D1 DE 60312684D1 DE 60312684 T DE60312684 T DE 60312684T DE 60312684 T DE60312684 T DE 60312684T DE 60312684 D1 DE60312684 D1 DE 60312684D1
Authority
DE
Germany
Prior art keywords
treatment
growth factor
plazenta
osteoporose
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60312684T
Other languages
English (en)
Other versions
DE60312684T2 (de
Inventor
Peter Carmeliet
Desire Collen
Roger Bouillon
Gertrudis Carmeliet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Desire Collen Research Foundation vzw
Original Assignee
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Desire Collen Research Foundation vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven, Vlaams Instituut voor Biotechnologie VIB, Desire Collen Research Foundation vzw filed Critical Katholieke Universiteit Leuven
Publication of DE60312684D1 publication Critical patent/DE60312684D1/de
Application granted granted Critical
Publication of DE60312684T2 publication Critical patent/DE60312684T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60312684T 2002-06-28 2003-06-27 Plazenta-wachstumsfaktor als target für die behandlung von osteoporose Expired - Lifetime DE60312684T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02077591 2002-06-28
EP02077591 2002-06-28
PCT/EP2003/050274 WO2004002524A1 (en) 2002-06-28 2003-06-27 Placental growth factor as a target for the treatment of osteoporosis

Publications (2)

Publication Number Publication Date
DE60312684D1 true DE60312684D1 (de) 2007-05-03
DE60312684T2 DE60312684T2 (de) 2007-12-06

Family

ID=29797249

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60312684T Expired - Lifetime DE60312684T2 (de) 2002-06-28 2003-06-27 Plazenta-wachstumsfaktor als target für die behandlung von osteoporose

Country Status (8)

Country Link
US (1) US7357929B2 (de)
EP (2) EP1517703B1 (de)
JP (1) JP2005535634A (de)
AT (1) ATE357255T1 (de)
AU (2) AU2003251728A1 (de)
CA (1) CA2491053A1 (de)
DE (1) DE60312684T2 (de)
WO (2) WO2004002525A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1297016T3 (da) * 2000-05-12 2006-07-10 Vlaams Interuniv Inst Biotech Anvendelse af placentavækstfaktorinhibitorer til behandling af patologisk angiogenese, patologisk arteriogenese, inflammation, tumordannelse og/eller vaskulær lækage
EP1614731B1 (de) 2004-07-05 2008-08-27 3M Innovative Properties Company Grundierung aus PTFE für Metallsubstrate
ES2565481T3 (es) 2005-03-24 2016-04-05 Thrombogenics N.V. Anticuerpo anti-PlGF novedoso
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
ES2628321T3 (es) 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
WO2014012165A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
US9149471B2 (en) * 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis
WO2017153567A1 (en) 2016-03-10 2017-09-14 Thrombogenics Nv Posterior ocular fibrosis inhibition by antagonizing placental growth factor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69322860T2 (de) 1992-04-03 1999-07-01 Genentech, Inc., South San Francisco, Calif. Antikörper gegen alpha v beta 3 integrin
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5670057A (en) 1995-04-28 1997-09-23 Baxter International Inc. Apparatus and method for automatically performing peritoneal equilibration tests
JP2001086982A (ja) * 1999-07-16 2001-04-03 Shunpei Niida 骨吸収調節薬
DK1297016T3 (da) 2000-05-12 2006-07-10 Vlaams Interuniv Inst Biotech Anvendelse af placentavækstfaktorinhibitorer til behandling af patologisk angiogenese, patologisk arteriogenese, inflammation, tumordannelse og/eller vaskulær lækage
AU2002316305A1 (en) * 2001-06-20 2003-01-08 Vlaams Interuniversitair Institut Voor Biotechnologie Method of treating atherosclerosis and other inflammatory diseases

Also Published As

Publication number Publication date
EP1517704A1 (de) 2005-03-30
AU2003251728A8 (en) 2004-01-19
US7357929B2 (en) 2008-04-15
US20050175609A1 (en) 2005-08-11
CA2491053A1 (en) 2004-01-08
EP1517703A1 (de) 2005-03-30
EP1517703B1 (de) 2007-03-21
AU2003251729A8 (en) 2004-01-19
JP2005535634A (ja) 2005-11-24
DE60312684T2 (de) 2007-12-06
WO2004002525A1 (en) 2004-01-08
AU2003251729A1 (en) 2004-01-19
WO2004002524A1 (en) 2004-01-08
ATE357255T1 (de) 2007-04-15
AU2003251728A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
DE602004013563D1 (de) Rantagonisten
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
EP1606286A4 (de) Benzodiazepinspirohydantoine als cgrp-rezeptorantagonisten
ATE435210T1 (de) Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
ATE374200T1 (de) 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
ATE414526T1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
DE60312684D1 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
DE60326069D1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
NO20055741D0 (no) Nye kjemiske forbindelser
TW200724140A (en) Hydantoin compounds
DE60112742D1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
AU2003210850A8 (en) N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition